Gastrointestinal Tract Links

Synergy Pharmaceuticals to Present Abstract at Digestive Disease Week 2012

NEW YORK -- Synergy Pharmaceuticals, Inc. , a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that a poster presentation will be given at the Digestive Disease ...

NPS Pharmaceuticals Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of ...

NPS Pharmaceuticals, Inc. , a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endoccrine disorders, today reported t

Cubist Announces First Scientific Presentations of Phase 2 Data for CB-5945 in the Treatment of Opioid-Induced ...

Cubist Pharmaceuticals, Inc. today announced that the results from the Phase 2 studies of CB-5945 in patients with chronic non-cancer pain and opi

Germs Behind Urinary Tract Infections Becoming More Resistant to Drugs

FRIDAY, May 4 (HealthDay News) -- E. coli bacteria's resistance to ciprofloxacin (Cipro), the most widely prescribed antimicrobial for urinary tract infections in the United States, increased five-fold between 2000 and 2010, according to a new study.

Crospon Recognised for Enabling Technology by Frost & Sullivan Awards

Crospon, a medical device developer based in Galway, Ireland has been recognised with the 2012 European Enabling Technology Award for Surgical Imaging Technology by Frost & Sul